Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating diffuse large b cell lymphoma

A B cell, diffuse technology, applied in chemical instruments and methods, drug combinations, antineoplastic drugs, etc., can solve problems such as poor prognosis and no clear standard of care

Pending Publication Date: 2020-05-29
MERCK SHARP & DOHME CORP +1
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Poor prognosis with no clear standard of care for patients who do not respond adequately to or are not candidates for severe salvage regimens or HSCT

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating diffuse large b cell lymphoma
  • Compositions and methods for treating diffuse large b cell lymphoma
  • Compositions and methods for treating diffuse large b cell lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0280] Example 1. Phase 1b open-label investigation of the safety and efficacy of blinatumomab in combination with pembrolizumab in adult subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Research

[0281] overview

[0282] The primary objective of the study was to determine the maximum tolerated dose (MTD) of the combination of blinatumomab and pembrolizumab in adult subjects with relapsed or refractory (r / r) DLBCL. The secondary objectives of the study were to evaluate the safety, efficacy and pharmacokinetics (PK) of blinatumomab in combination with pembrolizumab in adult subjects with r / r DLBCL.

[0283] The overlay hypothesis is that the combination of blinatumomab and pembrolizumab is tolerated in r / r DLBCL.

[0284] The primary endpoint was the incidence of dose-limiting toxicity (DLT). Secondary endpoints were: Overall Response Rate (ORR) by Cheson Criteria (2007); Complete Response (CR) by Cheson Criteria; Duration of Response (DOR) by ORR,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and compositions for treating diffuse large B cell lymphoma (DLBCL) using a combination of blinatumomab and / or a blinatumomab variant and pembrolizumab, a pembrolizumab variant and / or an antigen-binding fragment thereof, are provided.

Description

[0001] related application [0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 571,870, filed October 13, 2017, which is hereby incorporated by reference in its entirety for all purposes. technical field [0003] The present invention relates to the field of cancer treatment. In particular, the invention relates to the use of combinations comprising blinatumomab and / or blinatumomab variants with pembrolizumab, pembrolizumab variants and / or antigen-binding fragments thereof Treatment to treat relapsed or refractory diffuse large B cell lymphoma (diffuse large B celllymphoma, DLBCL). Background technique [0004] In Europe and the United States, the annual incidence of non-Hodgkin lymphoma (NHL) is estimated at 15 to 20 cases per 100,000 (Fisher and Fisher, 2004). DLBCL is the most common lymphoid malignancy in adults, accounting for 31% of all NHLs in Western countries and 37% of all B-cell neoplasms worldwide (NHL classification ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61K39/395A61P35/00
CPCA61K31/573C07K16/2803C07K16/2809C07K16/2818A61K2039/507A61K2039/545A61K2039/55A61K2039/585C07K2317/24C07K2317/31C07K2317/622A61P35/02A61K2300/00A61P35/00A61K2039/54
Inventor 扎卡里·齐默尔曼晓红·阿莉西亚·张彼得·克里斯托弗·霍兰珍妮特·富兰克林格雷戈里·弗里贝里
Owner MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com